Edition:
India

Intellia Therapeutics Inc (NTLA.OQ)

NTLA.OQ on NASDAQ Stock Exchange Global Market

22.31USD
10:50pm IST
Change (% chg)

$1.65 (+7.99%)
Prev Close
$20.66
Open
$20.80
Day's High
$22.33
Day's Low
$20.71
Volume
128,700
Avg. Vol
168,192
52-wk High
$33.20
52-wk Low
$10.83

Chart for

About

Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that... (more)

Overall

Beta: --
Market Cap(Mil.): $1,116.97
Shares Outstanding(Mil.): 36.11
Dividend: --
Yield (%): --

Financials

BRIEF-Intellia Therapeutics prices public offering of 6.3 mln shares at $24 per share

* Intellia Therapeutics announces pricing of public offering of common stock

02 Nov 2017

BRIEF-Intellia Therapeutics announces proposed public offering of common stock

* Intellia therapeutics announces proposed public offering of common stock

01 Nov 2017

BRIEF-Intellia Therapeutics Q3 loss per share $‍0.44​

* Intellia therapeutics announces third quarter 2017 financial results

31 Oct 2017

BRIEF-Intellia Therapeutics Q3 revenue $65 mln

* Intellia Therapeutics announces third quarter 2017 financial results

31 Oct 2017

BRIEF-Intellia Therapeutics announces patent for CRISPR/CAS genome editing in China

* Intellia Therapeutics announces patent for CRISPR/CAS genome editing in China

19 Jun 2017

BRIEF-Intellia Therapeutics and San Raffaele University and Research Hospital to combine CRISPR/cas9 genome editing with enhanced cell therapies

* Intellia Therapeutics and San Raffaele University And Research Hospital to combine CRISPR/cas9 genome editing with enhanced cell therapies to fight cancer Source text for Eikon: Further company coverage:

06 Jun 2017

BRIEF-Intellia Therapeutics files for mixed shelf of up to $250 mln

* Intellia Therapeutics Inc files for mixed shelf of up to $250 million – sec filing Source text - http://bit.ly/2qRiQLT Further company coverage:

06 Jun 2017

Earnings vs. Estimates